Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
Eur Urol Focus. 2021 May;7(3):644-652. doi: 10.1016/j.euf.2020.05.003. Epub 2020 May 23.
Recent data showed that North America has the highest incidence of renal cell carcinoma (RCC) worldwide.
To assess contemporary gender-, race-, and stage-specific incidence; survival rates; and trends of RCC patients in the USA.
DESIGN, SETTING, AND PARTICIPANTS: Within the Surveillance, Epidemiology, and End Results database (2001-2016), all patients aged ≥18 yr with histologically confirmed renal parenchymal tumors were included.
Age-adjusted incidence rates and 5-yr cancer-specific survival (CSS) rates were estimated. Temporal trends were calculated through Joinpoint regression analyses to describe the average annual percent change (AAPC).
The age-adjusted incidence rate of RCC was 11.3/100 000 person years (AAPC+2.0%, p<0.001). Five-year CSS rates increased from 78.4% to 84.5% (AAPC +0.8%, p<0.001). Male incidence was double that of females (15.5 and 7.7, respectively). CSS marginally favored females (84.5% vs 82.0%), but improved equally in both genders (both AAPC +0.8%). The highest incidence (14.1/100 000 person years, AAPC +2.8%) and lowest survival (80.1%) were recorded in non-Hispanic American Indian/Alaska Native populations. T1aN0M0 had the highest incidence rates (4.6/100 000 person years), the highest increase over time (AAPC +3.6%), and the highest CSS (97.6%) of all stages. Limitations include retrospective nature and lack of information on risk factors.
The incidence of RCC increased significantly from 2001 to 2016, and 5-yr CSS after RCC improved. This was mainly due to T1aN0M0 tumors that showed the highest increase in the incidence and highest CSS. Unfavorable outcomes in specific ethnic groups warrant further research.
We examined contemporary incidence and cancer-specific survival rates of kidney cancer. Males had double the incidence rates of females, but lower survival. Natives showed the highest incidence rates and the lowest survival rates. Small renal masses showed the highest incidence and survival rates.
最近的数据显示，北美是全球肾癌（RCC）发病率最高的地区。
评估美国当代按性别、种族和分期划分的 RCC 发病率、生存率和趋势。
设计、地点和参与者：在监测、流行病学和结果数据库（2001-2016 年）中，所有年龄≥18 岁且经组织学证实为肾实质肿瘤的患者均被纳入研究。
估计了年龄调整后的发病率和 5 年癌症特异性生存率（CSS）。通过 Joinpoint 回归分析计算时间趋势，以描述平均年百分比变化（AAPC）。
RCC 的年龄调整发病率为 11.3/100000 人年（AAPC+2.0%，p<0.001）。5 年 CSS 率从 78.4%增加到 84.5%（AAPC+0.8%，p<0.001）。男性发病率是女性的两倍（分别为 15.5 和 7.7）。CSS 略有利于女性（84.5%比 82.0%），但两性的改善程度相同（均为 AAPC+0.8%）。非西班牙裔美国印第安人/阿拉斯加原住民的发病率最高（14.1/100000 人年，AAPC+2.8%），生存率最低（80.1%）。T1aN0M0 分期的发病率最高（4.6/100000 人年），随时间推移的增长率最高（AAPC+3.6%），所有分期中 CSS 最高（97.6%）。局限性包括回顾性研究和缺乏危险因素信息。
2001 年至 2016 年，RCC 的发病率显著增加，RCC 后的 5 年 CSS 有所改善。这主要归因于 T1aN0M0 肿瘤，其发病率和 CSS 均有最高增幅。特定族裔群体的不良预后值得进一步研究。
我们研究了当代肾癌的发病率和癌症特异性生存率。男性的发病率是女性的两倍，但生存率较低。原住民的发病率最高，生存率最低。小的肾肿瘤的发病率和生存率最高。
